What is Cytoo?
CYTOO is a biotechnology firm specializing in the advancement of muscle pathology research. Leveraging its proprietary MyoScreen platform, the company expedites the identification of drug targets and fosters therapeutic innovation. CYTOO provides a comprehensive suite of services, including disease modeling, target validation, hit identification, lead profiling, and functional potency assays. Its innovative CYTOOchips and CYTOOplates are engineered to generate physiologically relevant cellular models, catering to the needs of pharmaceutical and biotechnology clients engaged in the study of genetic, metabolic, and neuromuscular disorders.
How much funding has Cytoo raised?
Cytoo has raised a total of $15.9M across 3 funding rounds:
Angel/Seed
$1.2M
Series B
$4.7M
Series C
$10M
Angel/Seed (2008): $1.2M with participation from CEA Valorisation, Expansinvest, and Rhône-Alpes-Creation
Series B (2009): $4.7M led by Auriga Partners and CEA Investissement
Series C (2011): $10M supported by Auriga Partners
Key Investors in Cytoo
CEA Valorisation
CEA Valorisation is an entity focused on commercializing technologies and innovations originating from the French Alternative Energies and Atomic Energy Commission (CEA), likely investing in deep-tech ventures.
Expansinvest
Expansinvest, established in 1986, is a French firm specializing in capital investment, development, and transmission, with a focus on supporting companies through various stages of their lifecycle.
Auriga Partners
Auriga Partners is a venture capital firm that invests in technology and life science companies, often focusing on early-stage and growth-stage opportunities.
What's next for Cytoo?
With the recent major strategic investment, Cytoo is poised for accelerated growth and enhanced research capabilities. This substantial capital infusion, part of its overall enterprise-level funding, will likely be directed towards expanding its MyoScreen platform's reach, further developing its CYTOOchips and CYTOOplates, and potentially forging new strategic partnerships within the pharmaceutical and biotechnology sectors. The company's focus on pioneering muscle pathology research positions it to address critical unmet needs in drug discovery for a range of debilitating conditions.
See full Cytoo company page
